Cel-Sci (CVM) chief executive Geert Kersten used a public letter to shareholders Thursday to express confidence in the outcome of an ongoing Phase 3 clinical trial involving its cancer immunotherapy.

Privately, Cel-Sci pitched a sale of its stock to institutional investors earlier this week, according to a source familiar with the deal. The proposed equity financing was aborted, but suggests Cel-Sci is more fearful about the future of the therapy, called Multikine, than it’s willing to say publicly.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • 1. On October 25, 2019, Mr. Kersten purchased $25,000 worth of restricted stock directly from the Company at the closing price on October 24, 2019, the most recent closing price available.

    Makes perfect sense since its a scam, right ADAM? Where are the bodies from the so called failed trial? WHY is the CEO buying RESTRICTED STOCK if the trial is failing?

    These intentional self-serving hit piece articles are truly pathetic and do StatNews a great disservice with its BIAS!

  • Total hogwash. Geert wouldnt respond to Adams email to answer why he TURNED DOWN hedgie financing so he does this? The illegality of what is going on here is disturbing and discredits StatNews greatly.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy